Literature DB >> 4046737

Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats.

J St-Louis, G Massicotte.   

Abstract

Relaxin is an ovarian polypeptide hormone which is present in large amounts in the rat during the second half of gestation. During this period, blood pressure declines markedly, especially in spontaneously-hypertensive rats (SHR). To test the hypothesis that relaxin might be implicated in this decrease in blood pressure, we infused the hormone in female non-pregnant rats by means of an osmotic mini pump. Our results show that intravenous infusion of purified rat relaxin (1.8 micrograms/day) markedly reduced systolic blood pressure for at least 5 or 6 days in SHR. This decrease was highly significant from 24 hours after the beginning of the infusion and remained significant after 5 days. Rat relaxin was ineffective in control Wistar-Kyoto rats (WKY). Infusion of purified porcine relaxin (3.0 micrograms/day) also diminished blood pressure in SHR, but the effect was less pronounced and developed more slowly, reaching statistical significance on the fourth day of infusion. SHR not receiving relaxin maintained their original systolic blood pressure throughout the experiment. These results indicate that relaxin is involved in the regulation of blood pressure during gestation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4046737     DOI: 10.1016/0024-3205(85)90251-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  21 in total

1.  Relaxin is a potent renal vasodilator in conscious rats.

Authors:  L A Danielson; O D Sherwood; K P Conrad
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 2.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 3.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 4.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

5.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

Review 6.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

Review 7.  Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia.

Authors:  Kirk P Conrad
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Autoradiographic localization of relaxin binding sites in rat brain.

Authors:  P L Osheroff; H S Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

10.  Relaxin-induced increased coronary flow through stimulation of nitric oxide production.

Authors:  T Bani-Sacchi; M Bigazzi; D Bani; P F Mannaioni; E Masini
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.